Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trisenox + DVd in Untreated Multiple Myeloma
NCT00201695Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jul 2004
- Primary completion
- Sep 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in multiple myeloma (MM), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Overall Response Rate at 4 months. Started Jul 2004; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00201695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201695.